- Home
- CCEL vs BIVI Comparison
CCEL vs BIVI Comparison
Compare CCEL & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- BIVI
- Stock Information
- Founded
- CCEL 1989
- BIVI 2013
- Country
- CCEL United States
- BIVI United States
- Employees
- CCEL N/A
- BIVI N/A
- Industry
- CCEL Managed Health Care
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- BIVI Health Care
- Exchange
- CCEL Nasdaq
- BIVI Nasdaq
- Market Cap
- CCEL 50.0M
- BIVI 45.1M
- IPO Year
- CCEL 1997
- BIVI N/A
- Fundamental
- Price
- CCEL $8.92
- BIVI $3.25
- Analyst Decision
- CCEL
- BIVI Strong Buy
- Analyst Count
- CCEL 0
- BIVI 2
- Target Price
- CCEL N/A
- BIVI $40.00
- AVG Volume (30 Days)
- CCEL 38.7K
- BIVI 16.9M
- Earning Date
- CCEL 11-19-2024
- BIVI 11-13-2024
- Dividend Yield
- CCEL 2.73%
- BIVI N/A
- EPS Growth
- CCEL N/A
- BIVI N/A
- EPS
- CCEL N/A
- BIVI N/A
- Revenue
- CCEL $31,838,476.00
- BIVI N/A
- Revenue This Year
- CCEL $3.97
- BIVI N/A
- Revenue Next Year
- CCEL $0.91
- BIVI N/A
- P/E Ratio
- CCEL N/A
- BIVI N/A
- Revenue Growth
- CCEL 1.95
- BIVI N/A
- 52 Week Low
- CCEL $3.67
- BIVI $1.04
- 52 Week High
- CCEL $9.50
- BIVI $58.20
- Technical
- Relative Strength Index (RSI)
- CCEL 73.46
- BIVI 62.20
- Support Level
- CCEL $7.00
- BIVI $2.46
- Resistance Level
- CCEL $9.43
- BIVI $3.61
- Average True Range (ATR)
- CCEL 0.69
- BIVI 0.34
- MACD
- CCEL 0.25
- BIVI 0.07
- Stochastic Oscillator
- CCEL 89.95
- BIVI 68.36
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.